Cell Therapy Fundamentals Day: Tuesday, September 17
8:00 am Morning Coffee & Networking
Fundamentals 101: Introducing Engineered Cell Immunotherapies
9:00 am Highlighting the First Generation of CAR-T Therapies & Outlining the Future Direction
Synopsis
- Lessons learned from the first generation of CAR-Ts and how they are changing cell therapy
- Broadening the spectrum of indications addressable with CAR-T
- The next step: unlocking the full power of cell therapies by engineering biological scenarios with genomic design of smart cells
9:30 am Understanding TCR Therapies Intricacies & Advantages
Synopsis
- Exploring the ability for T-cell receptor therapies to target intracellular targets
- Identifying optimal TCRs for tumor specific antigens while navigating HLA restrictions
- Comparing cell and bispecific modalities to pinpoint benefits
10:00 am Outlining the Progress of TIL Therapies
Synopsis
- Exploring the ability for T-cell receptor therapies to target intracellular targets
- Identifying optimal TCRs for tumor specific antigens while navigating HLA restrictions
- Comparing cell and bispecific modalities to pinpoint benefits
10:30 am Morning Break & Networking
Evaluating Cell Therapy Delivery to Strengthen Strategy & Understand Priorities
11:30 am Panel Discussion: Allogeneic vs Autologous vs In Vivo: How will these Co-Exist?
Synopsis
- Comparing advantages and limitations of each approach to determine optimal applications
- Discussing key challenges faced by each approach to enlighten considerations in development
- Unearthing novel methods to advance efficacies in both approaches
12:00 pm Importance of Patient Centric Strategies in Commercialization
Synopsis
- Mapping the patient journey and key stakeholders in the journey
- Identifying key patient populations and unmet needs
- Working in cross functional teams to address complex hurdles
12:30 pm Lunch Break & Networking
Exploring Next Generation Advances to Turbocharge Future Cell Therapy Products
1:30 pm In Vivo Engineering of Immune Cells with mRNA LNP
Synopsis
- Specificity and efficiency of delivering mRNA to T-cells in vivo
- In vivo production of functional CAR-T cells
- In vivo CAR-T cell functionality in oncology and autoimmune settings
2:00 pm Leveraging Synthetic Biology & Machine Learning to De-Risk, Scale, & Screen Ultra Large Human Observed TCR Libraries
Synopsis
- Using variational synthesis to create unprecedented ultra large high accuracy libraries of human observed sequences
- Using multi-parametric synthetic biology techniques to engineer human cells and screen
- Using machine learning to iterate through library designs and tune composition towards desired function
2:30 pm Afternoon Break & Networking
Highlighting the Targeting Opportunity for Cell Therapies by Exploring Indications Beyond Heme
3:00 pm Unlocking the Challenges in Targeting Solid Tumor & Unveiling Approaches to Overcome These
Synopsis
- Adapting cells to overcome tumor antigen evasion
- Understanding the barrier that the tumor microenvironment creates
- Outlining strategies to equip cells for enhanced persistence, durability, and efficacy
3:30 pm Moving Beyond Oncology: The Opportunity of Autoimmune Diseases
Synopsis
- Developing CAR-T therapies for autoimmune diseases
- The role of B-cells and plasma cells in autoimmunity and understanding the pathophysiology of the different diseases
- Regulatory considerations when treating patients with long-term diseases